Explore the Primary Resistance Mechanisms of Anaplastic Lymphoma Kinase Inhibitors

Lung cancer is the most common cause of cancer death in Taiwan and worldwide [1]. The traditional chemotherapy, platinum-doublet chemotherapy, provided limited survival benefit. In the recent decades, the major evolution in lung cancer is the molecular subtyping of NSCLC, especially lung adenocarcinoma, which has resulted in a paradigm shift in the management of patients in advanced disease. The target therapy provided better treatment response and longer overall survival. For example, patients with NSCLC harboring Epidermal growth factor receptor (EGFR) mutations can get remarkable benefit and longer survival from EGFR tyrosine kinase inhibitors (TKIs) treatment comparing with the traditional platinum-base chemotherapy [2].

Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of NSCLC, typically occurring in younger, non-smoking individuals with adenocarcinoma histology [3]. The discovery of ALK fusions, particularly EML4-ALK, revolutionized the treatment of these patients with the development of ALK TKIs. First-generation ALK inhibitors, such as crizotinib, demonstrated remarkable initial responses, significantly improving progression-free survival (PFS) compared to standard chemotherapy [4]. However, the emergence of resistance, both primary and acquired, remains a major clinical challenge.

Primary resistance, defined as the lack of initial response or early progression within the first few months of ALK TKI therapy, occurs in a subset of patients and represents a significant obstacle to optimal treatment outcomes [5]. Primary resistance to ALK inhibition occurs, even with advanced TKI therapies, when the best clinical outcome is disease progression. Notably, approximately 5-7% of patients following crizotinib, 9% following ceritinib, and 25% following lorlatinib demonstrated a lack of response, and in these cases, no identifiable ALK mutations were detected [6]. Unlike acquired resistance, which typically arises from secondary mutations within the ALK kinase domain or activation of bypass signaling pathways, the mechanisms underlying primary resistance are less well understood.

Several potential factors contribute to primary resistance. One key aspect involves inherent tumor heterogeneity. NSCLC tumors are complex ecosystems with diverse subclones, some of which may harbor pre-existing genetic alterations that confer resistance to ALK inhibition [7]. These alterations might include co-occurring mutations in genes involved in cell signaling pathways, such as KRAS, EGFR, or TP53, which can bypass ALK dependence [6]. Furthermore, variations in ALK fusion isoforms or copy number alterations may also influence initial drug sensitivity. For example, some less common ALK fusion variants might possess distinct structural properties that reduce their affinity for ALK TKIs.

Another potential mechanism involves the tumor microenvironment (TME). The TME, composed of stromal cells, immune cells, and extracellular matrix, plays a critical role in tumor growth and drug response [8]. Components of the TME, such as cancer-associated fibroblasts (CAFs) and immunosuppressive cells, can secrete growth factors and cytokines that activate alternative signaling pathways, thereby promoting resistance to ALK inhibition. Additionally, the TME can create a physical barrier that limits drug penetration and efficacy.